An engineered factor Va prevents bleeding induced by anticoagulant wt activated protein C

PLoS ONE

Volumn 9, Issue 8, 2014, Pages

  Von Drygalski, Annette ^a,b   Bhat, Vikas ^a,b   Gale, Andrew J ^a   Burnier, Laurent ^a,c   Cramer, Thomas J ^b   Griffin, John H ^a,b   Mosnier, Laurent O ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; BLOOD CLOTTING FACTOR 5A; CYSTEINE; DROTRECOGIN; GLUTAMINE; THROMBIN; ANTICOAGULANT AGENT; PROTEIN C; RECOMBINANT PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLEEDING; BLOOD CLOTTING TIME; CHEMOPROPHYLAXIS; CONTROLLED STUDY; DISULFIDE BOND; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; EX VIVO STUDY; FEMALE; GENE MUTATION; HUMAN; IN VIVO STUDY; LIVER INJURY; MALE; MOUSE; NONHUMAN; PROTEIN ENGINEERING; ANIMAL; BLOOD CLOTTING; DRUG EFFECTS; HEMORRHAGE; HEMOSTASIS; METABOLISM; MORTALITY; PROTHROMBIN TIME;

ANIMALS; ANTICOAGULANTS; BLOOD COAGULATION; FACTOR VA; FEMALE; HEMORRHAGE; HEMOSTASIS; MICE; MODELS, ANIMAL; PROTEIN C; PROTHROMBIN TIME; RECOMBINANT PROTEINS; THROMBIN;

EID: 84940233194     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0104304     Document Type: Article

References (31)

1. von Drygalski A CT, Bhat V, Griffin JH, Gale AJ, Mosnier LO (2014) Improved hemostasis in hemophilia mice by means of an engineered factor Va mutant. J Thromb Haemost pp. 363-372.
2. Nesheim ME, Taswell JB, Mann KG (1979) The contribution of bovine Factor V and Factor Va to the activity of prothrombinase. J Biol Chem 254: 10952-10962. (Pubitemid 10163282)
3. Kalafatis M, Rand MD, Mann KG (1994) The mechanism of inactivation of human factor V and human factor Va by activated protein C. J Biol Chem 269: 31869-31880. (Pubitemid 24379561)
4. Nicolaes GA, Tans G, Thomassen MC, Hemker HC, Pabinger I, et al. (1995) Peptide bond cleavages and loss of functional activity during inactivation of factor Va and factor VaR506Q by activated protein C. J Biol Chem 270: 21158-21166.
5. Bernard GR, Macias WL, Joyce DE, Williams MD, Bailey J, et al. (2003) Safety assessment of drotrecogin alfa (activated) in the treatment of adult patients with severe sepsis. Crit Care 7: 155-163. (Pubitemid 36432674)
6. Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, et al. (2001) Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 344: 699-709. (Pubitemid 32204987)
7. Kerschen EJ, Fernandez JA, Cooley BC, Yang XV, Sood R, et al. (2007) Endotoxemia and sepsis mortality reduction by non-anticoagulant activated protein C. J Exp Med 204: 2439-2448. (Pubitemid 47529328)
8. Mosnier LO, Yang XV, Griffin JH (2007) Activated protein C mutant with minimal anticoagulant activity, normal cytoprotective activity, and preservation of thrombin activable fibrinolysis inhibitor-dependent cytoprotective functions. J Biol Chem 282: 33022-33033. (Pubitemid 350159287)
9. Gale AJ, Xu X, Pellequer JL, Getzoff ED, Griffin JH (2002) Interdomain engineered disulfide bond permitting elucidation of mechanisms of inactivation of coagulation factor Va by activated protein C. Protein Sci 11: 2091-2101. (Pubitemid 34919613)
10. Cramer TJ, Griffin JH, Gale AJ (2010) Factor V is an anticoagulant cofactor for activated protein C during inactivation of factor Va. Pathophysiol Haemost Thromb 37: 17-23.
11. Burnier L, Fernández JA, Griffin JH (2013) Antibody SPC-54 provides acute in vivo blockage of the murine protein C system. Blood Cells Mol Dis 50: 252-258.
12. Gale AJ, Sun X, Heeb MJ, Griffin JH (1997) Nonenzymatic anticoagulant activity of the mutant serine protease Ser360Ala-activated protein C mediated by factor Va. Protein Sci 6: 132-140. (Pubitemid 27045252)
13. Mosnier LO, Gale AJ, Yegneswaran S, Griffin JH (2004) Activated protein C variants with normal cytoprotective but reduced anticoagulant activity. Blood 104: 1740-1744. (Pubitemid 39202282)
14. Mosnier LO (2011) Platelet factor 4 inhibits thrombomodulin-dependent activation of thrombin-activatable fibrinolysis inhibitor (TAFI) by thrombin. J Biol Chem 286: 502-510.
15. Hemker H, Giesen P, AlDieri R, Regnault V, de Smed E, et al. (2002) The Calibrated Automated Thrombogram (CAT): A universal routine test for hyper- and hypocoagulability. Pathophysiology of Haemostasis and Thrombosis 32: 249-253. (Pubitemid 37490547)
16. Heeb MJ, Schwarz HP, White T, Lammle B, Berrettini M, et al. (1988) Immunoblotting studies of the molecular forms of protein C in plasma. Thromb Res 52: 33-43. (Pubitemid 18267485)
17. Shibata M, Kumar SR, Amar A, Fernandez JA, Hofman F, et al. (2001) Anti-inflammatory, antithrombotic, and neuroprotective effects of activated protein C in a murine model of focal ischemic stroke. Circulation 103: 1799-1805. (Pubitemid 32291419)
18. Fernandez JA, Heeb MJ, Xu X, Singh I, Zlokovic BV, et al. (2009) Species-specific anticoagulant and mitogenic activities of murine protein S. Haematologica 94: 1721-1731.
19. Lu G, DeGuzman F, Hollenbach S, Karbarz M, Abe K, et al. (2013) A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa. Nature Medicine 19: 446-+.
20. Karakaya K, Ucan H, Tascilar O, Emre A, Cakmak G, et al. (2009) Evaluation of a New Hemostatic Agent Ankaferd Blood Stopper in Experimental Liver Laceration. Journal of Investigative Surgery 22: 201-206.
21. Charbonneau S, Lemarie C, Peng H, Ganopolsky J, Shek P, et al. (2012) Surface-attached amphipathic peptides reduce hemorrhage in vivo. Journal of Trauma and Acute Care Surgery 72: 136-142.
22. Bajaj M, Ogueli G, Kumar Y, Vadivel K, Lawson G, et al. (2011) Engineering Kunitz Domain 1 (KD1) of Human Tissue Factor Pathway Inhibitor-2 to Selectively Inhibit Fibrinolysis PROPERTIES OF KD1-L17R VARIANT. Journal of Biological Chemistry 286: 4329-4340.
23. Jasuja GK, Reisman JI, Miller DR, Berlowitz DR, Hylek EM, et al. (2013) Identifying major hemorrhage with automated data: results of the Veterans Affairs study to improve anticoagulation (VARIA). Thromb Res 131: 31-36.
24. Geiger H, Pawar SA, Kerschen EJ, Nattamai KJ, Hernandez I, et al. (2012) Pharmacological targeting of the thrombomodulin-activated protein C pathway mitigates radiation toxicity. Nat Med 18: 1123-1129.
25. Chesebro BB, Rahn P, Carles M, Esmon CT, Xu J, et al. (2009) Increase in activated protein C mediates acute traumatic coagulopathy in mice. Shock 32: 659-665.
26. Davenport R (2013) Pathogenesis of acute traumatic coagulopathy. Transfusion 53 Suppl 1: 23S-27S.
27. Christiaans SC, Duhachek-Stapelman AL, Russell RT, Lisco SJ, Kerby JD, et al. (2014) Coagulopathy after severe pediatric trauma: A review. Shock.
28. Schlachterman A, Schuettrumpf J, Liu JH, Furlan Freguia C, Toso R, et al. (2005) Factor V Leiden improves in vivo hemostasis in murine hemophilia models. J Thromb Haemost 3: 2730-2737. (Pubitemid 41819802)
29. Mann KG, Jenny RJ, Krishnaswamy S (1988) Cofactor proteins in the assembly and expression of blood clotting enzyme complexes. Annu Rev Biochem 57: 915-956.
30. Franchini M, Lippi G (2010) Factor V Leiden and hemophilia. Thromb Res 125: 119-123.
31. Lyden P, Levy H, Weymer S, Pryor K, Kramer W, et al. (2013) Phase 1 safety, tolerability and pharmacokinetics of 3K3A-APC in healthy adult volunteers. Curr Pharm Des 19: 7479-7485.